Literature DB >> 9382731

Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge.

F Schödel1, D Peterson, D R Milich, Y Charoenvit, J Sadoff, R Wirtz.   

Abstract

The hepatitis B virus nucleocapsid antigen (HBcAg) was investigated as a carrier moiety for circumsporozoite protein (CS) repeat B cell epitopes of the rodent malaria agent Plasmodium yoelii. A vector expressing a hybrid gene coding for the dominant CS repeat epitope (QGPGAP)4 was constructed and transformed into avirulent Salmonella typhimurium. The resulting hybrid HBcAg-CS polyproteins were purified from recombinant Salmonella typhimurium. They purified as particles and displayed HBc as well as P. yoelii CS antigenicity. To investigate immunogenicity and protective efficacy, BALB/c mice were immunized with the hybrid HBcAg-CS particles. Immunization resulted in high titered antinative CS serum IgG antibody litres. BALB/c mice immunized with hybrid HBcAgCS particles were between 90-100% protected against subsequent P. yoelli challenge. Protective immunity persisted for a minimum of three months. These data confirm the previous suggestion (Schödel et al., 1994), that hybrid HBcAg particles could become a useful component of future human malaria vaccines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382731

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  8 in total

1.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

3.  A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.

Authors:  A Birkett; K Lyons; A Schmidt; D Boyd; G A Oliveira; A Siddique; R Nussenzweig; J M Calvo-Calle; E Nardin
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.

Authors:  Giane A Oliveira; Kristiane Wetzel; J Mauricio Calvo-Calle; Ruth Nussenzweig; Annette Schmidt; Ashley Birkett; Filip Dubovsky; Eveline Tierney; Christoph H Gleiter; Gabriele Boehmer; Adrian J F Luty; Michael Ramharter; George B Thornton; Peter G Kremsner; Elizabeth H Nardin
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

Authors:  Elizabeth H Nardin; Giane A Oliveira; J Mauricio Calvo-Calle; Kristiane Wetzel; Carolin Maier; Ashley J Birkett; Pramod Sarpotdar; Michael L Corado; George B Thornton; Annette Schmidt
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 6.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

7.  P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.

Authors:  David C Whitacre; Diego A Espinosa; Cory J Peters; Joyce E Jones; Amy E Tucker; Darrell L Peterson; Fidel P Zavala; David R Milich
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

8.  Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.

Authors:  Aric L Gregson; Giane Oliveira; Caroline Othoro; J Mauricio Calvo-Calle; George B Thorton; Elizabeth Nardin; Robert Edelman
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.